CSL Ltd Annual Report 2019

Elizabeth Walker BA, MS (Organisational Development and Leadership) Age 49 Executive Vice President, Chief Human Resources Officer Elizabeth was appointed as Chief Human Resources Officer in December 2017. She joined CSL Behring as Chief Talent Officer in 2016 and served as interim Chief Human Resources Officer fromOctober 2017. Prior to joining CSL, Elizabeth was Vice President Global Talent Management at Campbell Soup Company. She has more than 25 years of experience in both management consulting and human resources. Elizabeth has worked across a variety of industries, including healthcare, financial services and food manufacturing. Bill Mezzanotte MD, MPH Age 60 Executive Vice President, Head Research & Development (from October 2018) Bill was appointed as Head of Research and Development in October 2018. He joined CSL as Head of Clinical Development in April 2017. Prior to CSL, Bill was Senior Vice President and Therapeutic Area Head, Respiratory for Boehringer Ingelheim and spent 16 years with AstraZeneca in research and development, assuming roles of increasing leadership and management responsibility across multiple therapeutic areas. Alan Wills BA (Zoology), MBA Age 55 Executive Vice President, Strategy and Business Development Alan joined the company in February 2015. He is responsible for strategy, portfolio management and business development activities at CSL. Prior to joining CSL, Alan was Executive Vice President, Corporate Development at Auxilium Pharmaceuticals. He was previously head of corporate strategy for Bristol-Myers Squibb and Pfizer, and has worked in strategy and business development roles at United Healthcare and Stanford Medical Center. Alan began his career with the Boston Consulting Group. Paul McKenzie PhD (Chemical Engineering) Age 53 Chief Operating Officer (from June 2019) Paul was appointed Chief Operating Officer in June 2019 and leads CSL’s global end-to-end operations organisation and its accompanying strategy. Prior to joining CSL, he served as Executive Vice President of Pharmaceutical Operations and Technology at Biogen. With more than 25 years of experience, Paul also held various senior roles in research and development and manufacturing for Johnson & Johnson, Bristol-Myers Squibb and Merck & Co. Anjana Narain BA (English), MBA Age 52 Executive Vice President and General Manager, Seqirus (from August 2019) Anjana was appointed as Executive Vice-President and General Manager of Seqirus in August 2019. She leads the global strategy for the Seqirus business as well as its end-to-end operations. Prior to joining CSL, Anjana spent nine years leading major businesses at GSK, including global influenza commercialisation, general management of vaccines and primary care. With more than 25 years of experience in vaccines and biopharmaceuticals, she has also held senior leadership roles at Merck & Co. and Bayer Inc., and been recognised for her work in inclusion and diversity. In 2018/19, Gordon Naylor retired from the organisation. Due to reporting line changes, Val Romberg and Karen Etchberger were no longer members of the GLG from 30 June 2019. More on CSL.com (Our Company > Board and Management) CSL Limited Annual Report 2019 47